FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 23 of 40
May 21, 2026The surge in GLP-1 drug utilization and associated costs poses challenges for employer-sponsored insurance plans that are self-insured. Strategic management approaches are needed to address the financial impact while supporting adolescent patients.
May 20, 2026As digital device use becomes ubiquitous in childhood, concerns have risen regarding its impact on development and well-being. The Surgeon General’s advisory highlights the emerging evidence on how excessive or improper screen time can pose real harm, inviting a coordinated response to protect pediatric populations.
May 20, 2026Persistent vacancies in key NIH leadership positions underscore challenges in agency governance and could affect health policy outcomes and research directions. The broader impact reverberates through related health agencies amid political and operational uncertainty.
May 19, 2026Amid ongoing debates over COVID-19 vaccine safety, especially in children, an FDA report has provided evidence that counters claims of fatal adverse events linked to pediatric COVID immunizations. This detailed examination summarizes the report, assesses its implications for public health policy, and discusses the broader challenge of misinformation in vaccine discourse.
May 19, 2026The No Surprises Act was created to protect consumers from unexpected medical billing disputes. However, recent concerns about abuses in the independent dispute resolution (IDR) process have prompted calls for regulatory reforms. This blog explores the coalition's concerns and the implications for payer-provider dynamics.
May 18, 2026AstraZeneca's recent FDA approval of Baxfendy brings forward a new class of hypertension drugs targeting aldosterone synthase. This approval not only offers hope to patients with high blood pressure but also represents AstraZeneca's strategic move amid looming patent expirations on its cardiometabolic portfolio.
May 18, 2026The emerging reports surrounding Amgen’s Tavneos drug spotlight the multifaceted challenges in pharmaceutical approvals, the critical importance of data transparency, and the potential repercussions for public health and corporate accountability.
May 18, 2026Recent changes in FDA leadership, marked by the swift departure of Katherine Szarama from CBER’s helm, highlight underlying tensions and ongoing reforms in regulatory oversight of biologics. This article analyzes the context, potential impacts on biopharma innovation, and public trust.
May 18, 2026New regulations central to the UK-US pharma trade deal have sparked significant concern among advocacy groups in the UK. These groups argue that the deal contains provisions that could negatively impact public health and access to medicines, prompting threats of court action unless the UK government revokes the controversial regulations. Such developments underscore the complexities at the intersection of trade agreements and healthcare policy.
May 17, 2026This article explores the parallels between the hantavirus outbreak and the Covid-19 pandemic, focusing on public perception, misinformation, and the broader implications for outbreak management and communication. It examines how the laneway of conspiracy theories re-emerged amid health crisis, echoing past challenges during the global pandemic.
May 17, 2026The recent announcement by WHO underscores significant international apprehension surrounding the Ebola outbreak spreading through the Democratic Republic of the Congo and Uganda. This declaration signals an increased urgency for coordinated global response efforts to contain the disease and mitigate further spread across borders.
May 15, 2026The FDA is experiencing significant leadership upheaval, highlighted by the recent resignations within its highest ranks. The exit of interim CDER head Tracy Beth Høeg shortly after Commissioner Makary's resignation raises questions about the agency’s internal dynamics and the potential impact on its regulatory functions. This article explores the circumstances and implications surrounding these high-profile departures at the FDA.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.